Cargando…
The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency
BACKGROUND: The major concept behind augmentation therapy with human α(1)-antitrypsin (AAT) is to raise the levels of AAT in patients with protease inhibitor phenotype ZZ (Glu342Lys)-inherited AAT deficiency and to protect lung tissues from proteolysis and progression of emphysema. OBJECTIVE: To eva...
Autores principales: | Schmid, ST, Koepke, J, Dresel, M, Hattesohl, A, Frenzel, E, Perez, J, Lomas, DA, Miranda, E, Greulich, T, Noeske, S, Wencker, M, Teschler, H, Vogelmeier, C, Janciauskiene, S, Koczulla, AR |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468059/ https://www.ncbi.nlm.nih.gov/pubmed/23055718 http://dx.doi.org/10.2147/COPD.S34560 |
Ejemplares similares
-
Survival in severe alpha-1-antitrypsin deficiency (PiZZ)
por: Tanash, Hanan A, et al.
Publicado: (2010) -
Therapy with Plasma Purified Alpha1-Antitrypsin (Prolastin(®)) Induces Time-Dependent Changes in Plasma Levels of MMP-9 and MPO
por: Koepke, Janine, et al.
Publicado: (2015) -
Fibrosis-Related Gene Profiling in Liver Biopsies of PiZZ α1-Antitrypsin Children with Different Clinical Courses
por: Kamp, Jan C., et al.
Publicado: (2023) -
Gene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency
por: Esquinas, Cristina, et al.
Publicado: (2017) -
Prevalence of α(1)-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review
por: Blanco, Ignacio, et al.
Publicado: (2020)